Study of immunotherapy and chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old and have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- Your cancer must be at an early stage (tumor not too deep or with some lymph node involvement, but not spread to distant organs).
- You should be in good physical condition (able to care for yourself and do most daily activities).
- Your cancer should not have been treated before with chemotherapy, radiation, or surgery.
- You must be planning to have surgery to remove the cancer after this treatment.
- Your overall health (blood counts, liver, kidney function) must be adequate, and you must not have major heart problems or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab (an immunotherapy) given before surgery to treat esophageal squamous cell cancer. It compares 2 cycles of treatment with 4 cycles to see which works better. The goal is to shrink the tumor and make surgery more effective.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
This trial tests whether giving an immunotherapy drug called adebrelimab (with other drugs) before surgery can help shrink the tumor and improve outcomes for people with a certain type of esophageal cancer. The goal is to make surgery more effective and potentially reduce the chance of cancer coming back.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.